{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"medRxiv"}],"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T19:51:12Z","timestamp":1768593072249,"version":"3.49.0"},"posted":{"date-parts":[[2021,12,13]]},"group-title":"Epidemiology","reference-count":33,"publisher":"openRxiv","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2021,12,13]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                <jats:p>Vaccination is considered the most important measure to control the COVID-19 pandemic. Extensive follow-up studies with distinct vaccines and populations are able to promote robust and reliable data to better understand the effectiveness of this pharmacologic strategy. In this sense, we present data regarding binding and neutralizing antibodies throughout time, from vaccinated and previously infected (PI) health care workers (HCW) in Portugal. We analyzed serum samples of 132 HCW, vaccinated and with previous SARS-CoV-2 infection. Samples were collected before vaccination (baseline, M1), at second dose vaccine uptake (M2), and 25-70 days (M3) and 150-210 days (M4) after the second dose for vaccinated individuals. The IgG (anti-RBD\/S) antibody geometric mean titer found on vaccinated HCW at M2 (814.7 AU\/ml; 95% CI 649.8-1021.5) were significantly higher than those found on PI HCW at recruitment (M1) (252.6 AU\/ml; 95% CI 108.7 - 587.1), and the neutralizing antibodies (nAb) were similar between these groups, 93.2 UI\/ml (95% CI 73.2-118.5) vs. 84.1 UI\/ml (95% CI 40.4-155.9), respectively. We detected about 10-fold higher IgG (anti-RBD\/S) antibodies titers in M3 when compared with M2, with a slightly but significant decrease in titers from 36 days after the second dose vaccine uptake. The increase of nAb titers were correlated with IgG (anti-RBD\/S) antibodies titers, however, contrasting to IgG (anti-RBD\/S) antibodies titers, we did not detect a decrease in nAb titer from 36 days after a second vaccine dose uptake. At M4, was observed a decrease of 8-fold in binding IgG (anti-RBD\/S) and nAb. No significant differences in antibody titers were observed by sex, age or chronic diseases. Our results suggest that IgG (anti-RBD\/S) antibodies titers and nAb titers could be correlated, but ongoing follow up of the cohort, is required to better understand this correlation, and the duration of the immune response.<\/jats:p>","DOI":"10.1101\/2021.12.10.21267607","type":"posted-content","created":{"date-parts":[[2021,12,13]],"date-time":"2021-12-13T12:55:24Z","timestamp":1639400124000},"source":"Crossref","is-referenced-by-count":8,"title":["High correlation between binding IgG (anti-RBD\/S) and neutralizing antibodies against SARS-CoV-2 six months after vaccination"],"prefix":"10.64898","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4563-6315","authenticated-orcid":false,"given":"Raquel","family":"Guiomar","sequence":"first","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0556-5513","authenticated-orcid":false,"given":"Ana Jo\u00e3o","family":"Santos","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6655-8715","authenticated-orcid":false,"given":"Aryse Martins","family":"Melo","sequence":"additional","affiliation":[]},{"given":"In\u00eas","family":"Costa","sequence":"additional","affiliation":[]},{"given":"Rita","family":"Matos","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2264-4723","authenticated-orcid":false,"given":"Ana Paula","family":"Rodrigues","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5772-2416","authenticated-orcid":false,"given":"Irina","family":"Kislaya","sequence":"additional","affiliation":[]},{"given":"Anabela Santos","family":"Silva","sequence":"additional","affiliation":[]},{"given":"Carla","family":"Roque","sequence":"additional","affiliation":[]},{"given":"Carla","family":"Silva","sequence":"additional","affiliation":[]},{"given":"Joaquim","family":"Aguiar","sequence":"additional","affiliation":[]},{"given":"F\u00e1tima","family":"Gra\u00e7a","sequence":"additional","affiliation":[]},{"given":"Ant\u00f4nio Silva","family":"Gra\u00e7a","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1849-1499","authenticated-orcid":false,"given":"Ausenda","family":"Machado","sequence":"additional","affiliation":[]}],"member":"54368","reference":[{"key":"2021121510501611000_2021.12.10.21267607v1.1","unstructured":"WHO Evaluation Of COVID-19 Vaccine Effectiveness. 2021, 70."},{"key":"2021121510501611000_2021.12.10.21267607v1.2","doi-asserted-by":"publisher","DOI":"10.1038\/s41418-020-00720-9"},{"key":"2021121510501611000_2021.12.10.21267607v1.3","unstructured":"INFARMED INFARMED COVID-19 -VACINAS APROVADAS (quadro resumo) 2021."},{"key":"2021121510501611000_2021.12.10.21267607v1.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2020.10.108"},{"key":"2021121510501611000_2021.12.10.21267607v1.5","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.627548"},{"key":"2021121510501611000_2021.12.10.21267607v1.6","doi-asserted-by":"publisher","DOI":"10.3390\/v13030422"},{"key":"2021121510501611000_2021.12.10.21267607v1.7","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-021-01924-7"},{"key":"2021121510501611000_2021.12.10.21267607v1.8","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.26982"},{"key":"2021121510501611000_2021.12.10.21267607v1.9","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00501-8"},{"key":"2021121510501611000_2021.12.10.21267607v1.10","doi-asserted-by":"crossref","unstructured":"Nicole Doria-Rose, P.D. ; (NIAID); Mehul S. Suthar, P.D. Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19. new Engl. J. o f Med. 2021, 384.","DOI":"10.1056\/NEJMc2103916"},{"key":"2021121510501611000_2021.12.10.21267607v1.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2021.05.063"},{"key":"2021121510501611000_2021.12.10.21267607v1.12","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-13889-6"},{"key":"2021121510501611000_2021.12.10.21267607v1.13","unstructured":"Dire\u00e7\u00e3o-Geral da Sa\u00fade Norma n\u00b0002\/2021 de 30\/01\/2021 atualizada a 21\/04\/2021; 2021;"},{"key":"2021121510501611000_2021.12.10.21267607v1.14","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01325-6"},{"key":"2021121510501611000_2021.12.10.21267607v1.15","unstructured":"et. al. Ana Paula Rodrigues, Ana Cristina Garcia Inqu\u00e9rito Serol\u00f3gico Nacional Relat\u00f3rio de apresenta\u00e7\u00e3o. 2021, 19."},{"key":"2021121510501611000_2021.12.10.21267607v1.16","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2027906"},{"key":"2021121510501611000_2021.12.10.21267607v1.17","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.8259"},{"key":"2021121510501611000_2021.12.10.21267607v1.18","doi-asserted-by":"publisher","DOI":"10.1111\/all.14364"},{"key":"2021121510501611000_2021.12.10.21267607v1.19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0249499"},{"key":"2021121510501611000_2021.12.10.21267607v1.20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2106599"},{"key":"2021121510501611000_2021.12.10.21267607v1.21","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2108891"},{"key":"2021121510501611000_2021.12.10.21267607v1.22","unstructured":"ECDC SARS-CoV-2 variants of concern as of 23 September 2021. ECDC 2021."},{"key":"2021121510501611000_2021.12.10.21267607v1.23","first-page":"2016","article-title":"Neutralizing Activity of BNT162b2-Elicited Serum To","volume":"69","author":"of T.M.","year":"2020","journal-title":"new Engl. J. o f Med"},{"key":"2021121510501611000_2021.12.10.21267607v1.24","doi-asserted-by":"crossref","unstructured":"Yang Liu, P.D. ; Jianying Liu, P.D. ; Hongjie Xia, P.D. ; Xianwen Zhang, B.S. ; Jing Zou, P.D. ; Camila R. Fontes-Garfias, P.D. ; Scott C. Weaver, P.D. ; Branch, U. of T.M.; Galveston, T.X. ; Kena A. Swanson, P.D. ; et al. BNT162b2-Elicited Neutralization against New SARS-CoV-2 Spike Variants. new Engl. J. o f Med. 2021, 385.","DOI":"10.1056\/NEJMc2106083"},{"key":"2021121510501611000_2021.12.10.21267607v1.25","first-page":"3","volume":"2","author":"Instituto Nacional de Sa\u00fade Doutor Ricardo Jorge, I.P","year":"2021","journal-title":"(INSA) Diversidade gen\u00e9tica do novo coronav\u00edrus SARS-CoV-2 (COVID-19) em Portugal"},{"key":"2021121510501611000_2021.12.10.21267607v1.26","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03777-9"},{"key":"2021121510501611000_2021.12.10.21267607v1.27","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01377-8"},{"key":"2021121510501611000_2021.12.10.21267607v1.28","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.ES.2021.26.38.2100833"},{"key":"2021121510501611000_2021.12.10.21267607v1.29","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00502-X"},{"key":"2021121510501611000_2021.12.10.21267607v1.30","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2021.101018"},{"key":"2021121510501611000_2021.12.10.21267607v1.31","doi-asserted-by":"publisher","DOI":"10.1126\/science.abd7728"},{"key":"2021121510501611000_2021.12.10.21267607v1.32","first-page":"811","article-title":"Immune life history, vaccination, and the dynamics of SARS-CoV-2 over the next 5 years","volume":"818","year":"2020","journal-title":"Science (80-.)"},{"key":"2021121510501611000_2021.12.10.21267607v1.33","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01540-1"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1101\/2021.12.10.21267607","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T14:31:48Z","timestamp":1768487508000},"score":1,"resource":{"primary":{"URL":"http:\/\/medrxiv.org\/lookup\/doi\/10.1101\/2021.12.10.21267607"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,13]]},"references-count":33,"URL":"https:\/\/doi.org\/10.1101\/2021.12.10.21267607","relation":{"is-preprint-of":[{"id-type":"doi","id":"10.3390\/vaccines10020154","asserted-by":"subject"}]},"subject":[],"published":{"date-parts":[[2021,12,13]]},"subtype":"preprint"}}